Iniciar sesión
Registrarse
Restablecer contraseña
Publicar y Distribuir
Soluciones de Publicación
Soluciones de Distribución
Temas
Arquitectura y diseño
Artes
Ciencias Sociales
Ciencias de la Información y Bibliotecas, Estudios del Libro
Ciencias de la vida
Ciencias de los materiales
Deporte y tiempo libre
Estudios clásicos y del Cercano Oriente antiguo
Estudios culturales
Estudios judíos
Farmacia
Filosofía
Física
Geociencias
Historia
Informática
Ingeniería
Interés general
Ley
Lingüística y semiótica
Literatura
Matemáticas
Medicina
Música
Negocios y Economía
Química
Química industrial
Teología y religión
Publicaciones
Revistas
Libros
Actas
Editoriales
Blog
Contacto
Buscar
EUR
USD
GBP
Español
English
Deutsch
Polski
Español
Français
Italiano
Carrito
Home
Revistas
Asian Biomedicine
Volumen 15 (2021): Edición 4 (August 2021)
Acceso abierto
Potential of amentoflavone with antiviral properties in COVID-19 treatment
Akhilesh Vikram Singh
Akhilesh Vikram Singh
| 20 ago 2021
Asian Biomedicine
Volumen 15 (2021): Edición 4 (August 2021)
Acerca de este artículo
Artículo anterior
Artículo siguiente
Resumen
Artículo
Figuras y tablas
Referencias
Autores
Artículos en este número
Vista previa
PDF
Cite
Compartir
Article Category:
Mini review
Publicado en línea:
20 ago 2021
Páginas:
153 - 159
DOI:
https://doi.org/10.2478/abm-2021-0020
Palabras clave
amentoflavone
,
COVID-19
,
CYP450 inhibitor
,
flavonoid
,
SARS-CoV
© 2021 Akhilesh Vikram Singh, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Figure 1
Molecular docking showing the binding of amentoflavone to the receptor binding domain of spike glycoprotein of SARS-CoV-2 (Research Collaboratory for Structural Bioinformatics Protein (RCSB) Data Base ID 6M17, chain E). Residues of the receptor binding domain interacting with amentoflavone are shown in yellow. Adapted from Miroshnychenko KV, Shestopalova A. Combined use of amentoflavone and ledipasvir could interfere with binding of spike glycoprotein of SARS-CoV-2 to ACE2: the results of molecular docking study. ChemRxiv. Preprint. doi: 10.26434/chemrxiv.12377870.v1, with kind permission of the authors. ACE2, angiotensin-converting enzyme 2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 2
Interaction of amentoflavone with the inflammatory network and CYPs. Network drawn using STITCH showing chemical–protein interactions based on literature. In the network, nodes are proteins or chemicals and the edges represent the functional associations. The grey edges represent confidence with the line thickness indicating the strength of data support. Adapted from http://stitch.embl.de [25]. Inset shows the binding of amentoflavone to SARS-CoV 3CLpro. Adapted minimally and reprinted from [17] Bioorganic and Medicinal Chemistry, 18, Young Bae Ryu, Hyung Jae Jeong, Jang Hoon Kim, Young Min Kim, Ji-Young Park, Doman Kim, Thi Thanh Hanh Naguyen, Su-Jin Park, Jong Sun Chang, Ki Hun Park, Mun-Chual Rho, Woo Song Lee, Biflavonoids from Torreya nucifera displaying SARS-Co V 3CLpro inhibition, page 7944, Copyright (2010), with permission from Elsevier. The network shows the association of amentoflavone with CYPs and the inflammatory pathway to support the hypothesis for using amentoflavone as an adjunct therapy for COVID-19. 3CLpro, 3-chymotrypsin-like protease; COVID-19, Coronavirus disease-2019; CYP, cytochrome P450; ERBB2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; GRB2, growth factor receptor-bound protein 2; HSP90AA1, heat shock protein 90α family class A member 1; IL1B, interleukin 1β; IL6, interleukin 6; IL6R, interleukin 6 receptor; IL6ST, interleukin 6 signal transducer; OPRD1, opioid receptor δ1; OPRM1, opioid receptor μ1; PPARG, peroxisome proliferator-activated receptor γ; SARS-CoV, severe acute respiratory syndrome coronavirus; TNF, tumor necrosis factor α.
Vista previa